Novonesis refines long-term enzyme strategy, shares trade steadily in Copenhagen

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-29, 13:11.

Novonesis (DK0060336014) sits in the biotechnology and industrial enzymes segment with a listing on Nasdaq Copenhagen, where the B shares most recently changed hands in the mid-50-euro range via German quotation platforms. The company outlines a long-term strategy centered on enzymes and microbes for food, agriculture and industrial uses according to its latest public materials.

What recent data show on Novonesis

On finanzen100, Novonesis B is quoted around 54.56 euros with a narrow bid-ask spread and a classification in the chemical sector with biotechnology exposure. The stock trades under the ticker NZM2 in Germany, while Copenhagen remains the primary venue.

The same data set highlights the WKN A1JP9Y for German investors and confirms Denmark as the issuer’s home market. This underlines Novonesis as a mid cap in the broader European specialty chemicals and life sciences universe, where peers include Novo Nordisk and Chr. Hansen in the extended Danish ecosystem.

Consensus and sector context on Monday

Sector peers such as Novo Nordisk, also listed in Copenhagen and represented by ADRs on the NYSE, continue to draw significant analyst attention with Deutsche Bank, among others, maintaining coverage and setting price targets in Danish kroner. This dense research activity on Danish life sciences underpins the broader visibility of companies like Novonesis, even if individual analyst notes on Novonesis are less frequently highlighted in public aggregators.

For Novo Nordisk, recent quotes around 41.7 euros for the B shares and roughly 48 dollars for the ADRs indicate steady large-cap appetite in European and US markets. These levels help frame the valuation corridor for Danish health-related names and illustrate how global investors benchmark mid caps like Novonesis against blue-chip peers in the same national cluster.

The products behind Novonesis

Novonesis focuses on enzyme and microbe solutions for applications in baking, dairy, brewing, grain processing and bioenergy, as presented on its website and investor materials. These biological products help customers improve yields, reduce energy use and support more sustainable production processes in food and industrial value chains.

Where the Novonesis shares trade today

The Novonesis B shares (DK0060336014) are most recently quoted around 54.56 euros via German platforms for the Nasdaq Copenhagen listing as of 2026-06-29, 12:31, taking the latest available price snapshot from finanzen100 as a reference.

This article is for informational purposes only and does not constitute investment advice, an offer or a solicitation to buy or sell any financial instrument. All data have been carefully researched but carry no guarantee. Investors should conduct their own research or consult a licensed financial advisor before making investment decisions.